• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App

    9/18/25 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    Implementation will enable users to purchase, schedule appointments for testing, and receive results of lab tests performed by Quest within the WHOOP app, supporting access to deeper health and performance insights.

    WHOOP, the human performance company, today announced that Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, will be the U.S. lab provider for WHOOP Advanced Labs, a new WHOOP feature that provides laboratory insights supporting health and performance. The offering will provide the option to purchase Quest's clinical laboratory testing, schedule an appointment for testing, and receive test results within the WHOOP app. WHOOP Advanced Labs is scheduled to launch this fall.

    WHOOP members will be able to purchase and schedule their Quest lab test for their WHOOP Advanced Labs subscription to analyze biomarkers — including those related to metabolism, hormones, inflammation, cardiovascular health, nutrient status, and more, directly through the WHOOP app. WHOOP currently provides biometric data to help members assess recovery, sleep, and training, and adding lab testing is designed to provide additional insights, including into preventable health concerns, that may be addressed through lifestyle changes. WHOOP members will access the types of clinical testing that physicians order, from Quest Diagnostics, to deliver patient care.

    "At WHOOP, we're committed to empowering our members with a highly comprehensive view into their health and performance," said John Sullivan, Chief Marketing Officer at WHOOP. "By bringing Quest's lab testing into the WHOOP experience, we're taking a pivotal step forward in helping people access and act on the power of blood testing to reveal insights into health, so they can live and perform closer to their potential for longer."

    "Health-minded consumers want insights from lab testing beyond the annual checkup," said Richard Adams, SVP, Quest Consumer. "Our collaboration with WHOOP is an example of how Quest is broadening access to deep health and wellness insights."

    To support consumer access, Quest has created a unique platform to be the lab engine inside consumer health experiences, whether that be through a wearable device, mobile app, or website.

    Quest operates approximately 2,000 patient service centers across the U.S. and also provides mobile phlebotomy access. A third-party provider will review the WHOOP member's request, order the test, provide the test results through the WHOOP app, and, on request, provide a phone consultation. Members can join the waitlist today at whoop.com/waitlist.

    About WHOOP

    WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP 5.0 and WHOOP MG offer groundbreaking health innovations, including cardiovascular health features; Healthspan which quantifies Pace of Aging and provides members with their WHOOP Age; and first-of-its-kind wearable Blood Pressure Insights. WHOOP is the perfect health companion for anyone looking to optimize their health and performance. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. WHOOP is available to ship in 56 markets worldwide and the WHOOP app is available in English, French, German, Italian and Spanish (Latin America). WHOOP can be purchased on Amazon across the U.S., U.K., and Australia, as well as Best Buy (U.S.) Dick's Sporting Goods (U.S.), Flipkart (India) and Virgin Megastore (GCC), and more.

    To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.

    About Quest Diagnostics

    Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250918065422/en/

    [email protected]

    [email protected]

    Get the next $DGX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    8/25/2025$194.00Outperform → Neutral
    Robert W. Baird
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    More analyst ratings

    $DGX
    SEC Filings

    View All

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/26/25 4:12:08 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    9/23/25 4:14:25 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 144 filed by Quest Diagnostics Incorporated

    144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    8/21/25 12:10:39 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health

    Over 350,000 members have joined the waitlist since May, underscoring the excitement for one product that can pair blood biomarkers with 24/7 wearable data WHOOP, the human performance company, today announced the launch of WHOOP Advanced Labs, a groundbreaking new feature that combines blood testing with continuous wearable data to deliver a complete picture of health. Members can upload past bloodwork results or schedule the company's curated Advanced Labs panel, which tests an extensive set of biomarkers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930178710/en/WHOOP Launches Clinician-Reviewed Advanced Labs, Unlockin

    9/30/25 9:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

    SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted

    9/25/25 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

    Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest's vast network Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant's Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Through a multi-year agreement, Quest's provider clients that

    9/24/25 8:05:00 AM ET
    $DGX
    $GH
    Medical Specialities
    Health Care

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & General Counsel Prevoznik Michael E exercised 28,463 shares at a strike of $103.57 and sold $5,326,042 worth of shares (28,463 units at $187.12) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    9/25/25 4:39:11 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick sold $365,375 worth of shares (1,975 units at $185.00), decreasing direct ownership by 11% to 15,269 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/25/25 4:27:59 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick exercised 4,532 shares at a strike of $112.17 and sold $829,356 worth of shares (4,532 units at $183.00) (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/21/25 4:34:05 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Quest Diagnostics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Quest Diagnostics from Outperform to Neutral and set a new price target of $194.00

    8/25/25 8:10:20 AM ET
    $DGX
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Citigroup with a new price target

    Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

    3/4/25 7:20:57 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

    SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

    3/3/23 4:30:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quotient Limited Announces Appointment of Chief Financial Officer

    JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

    10/12/21 8:45:00 AM ET
    $DGX
    $QTNT
    Medical Specialities
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

    SECAUCUS, N.J., Sept. 25, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report third quarter 2025 financial results on Tuesday, October 21, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted

    9/25/25 10:00:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to ta

    8/13/25 6:35:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

    Second quarter revenues of $2.76 billion, up 15.2% from 2024Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024Year-to-date cash provided by operations of $858 million, up 67.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83SECAUCUS, N.J., July 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025.

    7/22/25 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care